Payers

Waiving the Medicaid Best Price Rule Could Boost Savings from a Commercial Value-Based Arrangement by $4 Billion.

Novartis AG will be able to make its Kymriah CAR-T cancer treatment available free of charge to certain U.S. patients without worrying about running afoul of federal anti-kickback statues.

Novartis' access program and payments for its CAR-T therapy Kymriah is not illegal in the U.S.

The draft guidance, issued for public consultation, does not recommend sapropterin for adults.

NICE rejects breast cancer drug upon review of additional evidence collected as part of the Cancer Drugs Fund (CDF) managed access agreement .

NICE recommends skin cancer drug Opdivo based on new cost-effectiveness data.

The agency determined that there were uncertainties around the cost-effectiveness of Zynteglo, with the cost estimate for the gene therapy considerably higher than what NICE normally considers an acceptable use of NHS resources.

NICE has recommended treatment options for severe pregnancy sickness for the first time.

In its February 2021 meeting, the Scottish Medicines Consortium (SMC) has accepted four new medicines for use by the NHS in Scotland.

As breakthrough drugs stream out of biopharmaceutical laboratories, how much they should cost and who will get access to them remain thorny issues.

The US reimbursement landscape has been shifting rapidly while COVID-19 once more refocused the spotlight on access to care in the country.

NICE has launched a public consultation on proposals for changes to the processes it uses to develop its guidance on medicines, medical devices, diagnostics and digital health technologies.

In a statement, NICE said that this is the third such consultation on proposals for changes to the methods and processes used to produce its guidance on health technologies.

The relationship between drug pricing for rare disease therapies and disease prevalence in Europe, taking a closer look at payer assessments of orphan drugs in Germany.

Lung cancer drug gains a NICE recommendation for NHS England routine commissioning after new clinical evidence collected through the Cancer Drugs Fund.